Wednesday, October 25, 2023 8:26:34 AM
TC BioPharm (PRNewsfoto/TC BioPharm)
Excellos was chosen after an extensive review process due to their ability to navigate the complex regulatory impediments between the UK and US which relate to the sourcing of donor material for allogeneic cell therapies. TCBP's clinical trial plans in the US were also impactful in the decision to engage a CDMO. The Company intends to expand the clinical trial efforts beyond AML in 2024 with additional IND filings, either as an independent sponsor or in conjunction with partners or investigator sponsored trials.
"We feel that Excellos is an ideal partner for TCBP, sharing our entrepreneurial spirit and belief in a collaborative effort to advance cell therapies globally," commented CEO Bryan Kobel. "We believe this step materially strengthens our ability to deliver on multiple clinical fronts and creates economic efficiencies within our production planning, while also maintaining our manufacturing autonomy for the final product. Our team is looking forward to the continued clinical and platform expansions in 2024, and anticipate multiple milestone achievements in the next 12 months for investors."
Excellos will provide TC BioPharm with allogeneic cell banks, a "middle-step" that bridges donor blood with the finished product. TC BioPharm will then utilize the allogeneic cell banks to manufacture the final product doses, freeze and ship to the US for storage at the various sites.
"Excellos is excited to partner with TCBP to enable novel cell therapies for a number of cancer indications," said David Wellis, Ph.D., CEO of Excellos. "We share the vision of starting with deeply characterized cells to create cGMP compliant cell banks, which ultimately may enhance clinical trial success and optimized final product. Excellos believes this type of partnership is commercially significant for therapeutic companies looking for end-to-end support from collection and analysis of starting material through commercial product, and it supports our recent launch of our validated commercial cell manufacturing facility in San Diego, California."
The production of the allogeneic cell banks by Excellos will significantly increase access to FDA compliant donors, expanding the current platform and streamlining delivery of TCB008 clinical trials. Expansion of this platform will support the anti-fungal and CAR-T proof of concept, both expected in 2024, first half and second half respectively.
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Warren Buffett
Recent TCBP News
- TCBP Announces Launch of Compassionate Use Program for TCB008 • PR Newswire (US) • 05/15/2024 12:30:00 PM
- TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds • PR Newswire (US) • 05/06/2024 05:01:00 PM
- TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies • PR Newswire (US) • 05/06/2024 12:30:00 PM
- TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies • PR Newswire (US) • 04/04/2024 12:32:00 PM
- TCBP Increasing Treatment Capacity with Expanded Manufacturing Process • PR Newswire (US) • 04/02/2024 12:30:00 PM
- TCBP Adjourns General Meeting Until a Later Date • PR Newswire (US) • 03/19/2024 12:30:00 PM
- TCBP Announces Exercise of Series D Warrants For Cash • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:30:38 AM
- Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" • PR Newswire (US) • 03/01/2024 01:30:00 PM
- /C O R R E C T I O N -- TC BioPharm/ • PR Newswire (US) • 02/27/2024 10:15:00 PM
- TCBP Announces Shareholder Update Call on March 5th 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
- TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial • PR Newswire (US) • 02/22/2024 02:32:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/20/2024 11:05:14 AM
- TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe • PR Newswire (US) • 02/15/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 07:48:40 PM
- TCBP Provides Shareholder Update and Highlights Upcoming Milestones • PR Newswire (US) • 02/14/2024 01:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/09/2024 08:26:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 02:16:48 PM
- TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' • PR Newswire (US) • 01/29/2024 01:30:00 PM
- TC BioPharm to Present at the Sequire Investor Summit • PR Newswire (US) • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:46:05 PM
- TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 01/04/2024 01:30:00 PM
- TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies • PR Newswire (US) • 01/03/2024 01:30:00 PM
- TC BioPharm Announces Closing of $3.5 Million Public Offering • PR Newswire (US) • 12/22/2023 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 10:14:09 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM